Pathways to Success in Oncology
White Paper
Jul 05, 2018
The emergence of oncology clinical pathways and impact on therapy utilization
In the U.S., oncology costs are rapidly rising as new, targeted therapies come to market. To combat these growing costs, health insurance payers have instituted clinical pathways as an additional tool for reining in spend and increasing leverage. This white paper from the IQVIA US Market Access Strategy Consulting group provides a brief background on the emergence of oncology clinical pathways, discusses why it matters to manufacturers in particular, and presents evidence that pathways may move the needle on therapy utilization in a rapidly evolving oncology market.